SVF
Level C· Early human research exploring benefitsProspective StudyPubMed

[Cell-assisted lipotransfer for breast augmentation: a report of 18 patients].

Wang L., Lu Y., Luo X., Fu MG., Hu X., Dong H.

Prospective Study with a reported sample of 18 on Facial Rejuvenation, published in Zhonghua Zheng Xing Wai Ke Za Zhi (2012) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Zhonghua Zheng Xing Wai Ke Za Zhi (2012)
Country
China
Reported sample size
18
Source database
PubMed
PMID
22497178
Citations
18

Abstract (original English)

To evaluate the clinical effect of cell-assisted lipotransfer (CAL) for breast augmentation. 18 patients accepted breast augmentation using CAL. 10 patients completed 6-month follow-up and were involved in the study. The adipose tissue was harvested from patients' thighs, flanks and lower abdomen with Lipokit. After standing, 250 ml fatty portion and 500 ml fluid portion of suction aspirates were processed according to the procedures reported in reference. Flow-cytometry was used to detect the percentage of adipose-derived stem cells(ADSCs) in distilled stromal vascular fraction (SVF). The differentiation function of cultured cells also was assessed. The breast volume and images were evaluated by using MRI before operation, 3 and 6 months after operation. The breast volume was marked as V0, V3 and V6 respectively. The resorption rate of transplanted adipose tissue for each breast was calculated and marked as R3 and R6. Averagely, the percentage of ADSCs in freshly distilled SVF was 41.67%. The in-vitro cultured cell grew well and could differentiate into fat, bone and cartilage. Statistics showed that V0, V3 and V6 was (416.19 +/- 40.43) ml, (551.72 +/- 59.86) ml and (538.81 +/- 68.35) ml respectively. R3 and R6 was (51.20 +/- 11.96)% and (54.22 +/- 12.73)%. There was significant difference between V3 and V0 (P < 0.05), V6 and V0. However, no significant difference was showed b

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AdipocytesAdipose TissueAdultCell DifferentiationCells, CulturedFemaleHumansMammaplastyMiddle AgedStem Cell Transplantation
Facial Rejuvenation
View on PubMed

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

View all: topic “cell-assisted lipotransfer breast”View all: author wangView all: year 2012

Related research